News Room
Media Contacts
1413 K Street NW, 4th Floor
Washington, D.C. 20005
Telephone: (202) 682-2640
Fax: (202) 682-2648
General Inquiries – nwhn@nwhn.org
Media Inquiries – media@nwhn.org
- “FDA’s Actions on Essure are Steps in the Right Direction” NWHN statement in response to FDA Draft GuidanceFebruary 29, 2016FOR IMMEDIATE RELEASE Contact: Cindy Pearson at cpearson@nwhn.org or 202.682.2640, ext. 0 Safe & effective contraception, including permanent contraception, is an essential component of women’s health and economic security. Women rely on the FDA to make sure that the risks of contraceptive methods are low, and well understood. Today, the FDA took important first steps to improve women’s ...
- National Women’s Health Network Urges Women to Resist “Cheap” Gimmicks for Losing Weight in the New YearJanuary 7, 2016FOR IMMEDIATE RELEASE Contact: Christina Cherel at ccherel@nwhn.org or 202.682.2640, ext 224 With the New Year often comes resolutions to lead happier – and healthier – lives. The National Women’s Health Network (“NWHN”) encourages women who have made New Year’s resolutions to lose weight to resist misleading claims about “diet drugs” and cheap gimmicks from drug companies ...
- National Women’s Health Network Condemns Violence Against Planned Parenthood Health Center in Colorado SpringsNovember 30, 2015FOR IMMEDIATE RELEASE Contact: Christina Cherel at ccherel@nwhn.org or 202.682.2640, ext 224 In response to the shootings at Planned Parenthood’s health center in Colorado Springs, the National Women’s Health Network’s Executive Director, Cynthia Pearson, issued the following statement: “Every woman should be able to receive, and clinicians should be able to provide, health care services without fearing violence. Our hearts ...
- Women’s Health Leader Available for Interviews on Poor Sales of Women’s Sex Drug Addyi and Launch of New CampaignNovember 18, 2015FOR IMMEDIATE RELEASE Contact: Nora Brodnitz at nora@wcsemail.com or 202-471-0043 “PASS ON THE PINK PILL OR PASS OUT!” (Washington, D.C.) In its first month on the market, the new female libido-boosting drug Addyi (flibanserin) has seen very poor sales; just 227 women have filled prescriptions for “the pink pill” promising to boost their sex drive. Compare that to 600,000 prescriptions of ...
- New Campaign Warns Women of Harm from Drug FDA Approved in AugustNovember 17, 2015FOR IMMEDIATE RELEASE To schedule an interview with Cindy Pearson contact: Sarah Courtney at sarah@wardcirclestrategies.com or 917-913-1994 Feminist Health Advocates Cite Unsafe Sex Drug for Women in Call for Next FDA Commissioner to Resist Political Pressure WASHINGTON, D.C. – As Dr. Robert Califf testifies before the Senate on his nomination for commissioner of the Food and Drug Administration, the National Women’s ...
- Warning of marginal benefits and serious side effects as drug sales beginNovember 12, 2015FOR IMMEDIATE RELEASE To schedule an interview with Cindy Pearson and Susan Wood: Sarah Courtney at sarah@wardcirclestrategies.com or 917-913-1994 “PASS ON THE PINK PILL – OR PASS OUT!” Health Advocates Issue Emergency Alert on Addyi: The New Sex Drug for Women WASHINGTON, DC – The consumer advocacy group National Women’s Health Network (NWHN) today issued its first ever Emergency Alert on Addyi (in four decades ...
- The National Women’s Health Network Continues to Express Deep Concern Over Addyi’s SafetyOctober 16, 2015FOR IMMEDIATE RELEASE Contact: Christina Cherel at ccherel@nwhn.org or (202) 682-2640 Washington, D.C. – Tomorrow, the first FDA-approved drug to treat hypoactive sexual desire disorder (HSDD) in premenopausal women will be available by prescription. The National Women’s Health Network (“the Network”) remains deeply concerned over the unanswered questions regarding Addyi’s interaction with alcohol and the drug’s ability to cause ...
- The National Women’s Health Network expresses profound disappointment with FDA’s decision to approve controversial sex drug.August 19, 2015FOR IMMEDIATE RELEASE Contact: Christina Cherel at ccherel@nwhn.org or (202) 682-2640 WASHINGTON, D.C. – The National Women’s Health Network (the Network) is profoundly disappointed with the U.S. Food and Drug Administration’s (FDA) decision to approve flibanserin, a proposed treatment for female sexual dysfunction, despite inadequate proof of effectiveness and questionable assurances of the drug’s safety. The FDA’s recommendation for ...
- The National Women’s Health Network Celebrates the Introduction of the Equal Access to Abortion Coverage in Health Insurance (EACH) Woman ActJuly 1, 2015FOR IMMEDIATE RELEASE Contact: Media@nwhn.org or Cindy Pearson at 301-938-0356 (Washington, D.C.) The National Women’s Health Network (“the Network”) boldly stands with All* Above All and our pro-choice Congressional champions to restore and sustain abortion coverage for low-income women. We celebrate the introduction of the Equal Access to Abortion Coverage in Health Insurance (EACH) Woman Act as ...
- National Women’s Health Network Urges the FDA to Oppose Twice-Rejected Female Sex DrugJune 3, 2015FOR IMMEDIATE RELEASE Contact: Cindy Pearson at 301-938-0356 or Coco Jervis at 202-407-0788 The National Women’s Health Network (“the Network”) urges the FDA to oppose the approval of Sprout Pharmaceutical’s female sexual dysfunction drug flibanserin. The Network has come to this position after careful consideration of newly disclosed research and thorough evaluation of the drug’s extensive and ...